Rhenium is a fascinating metal with a rich coordination chemistry and its isotopes have shown great potential for use in radiotherapy. The isotope 188Re is particularly interesting as it emits high-energy beta particles (Emax = 2.12 MeV), making it perfect for radiotherapy of large tumours. The short half-life (t1/2 = 16.9 h) of rhenium-188 also allows it to be used in targeted radionuclide therapy when linked to peptides or antibodies. Additionally, rhenium-188 also decays with a 155 keV (15%) gamma emission suitable for imaging and dosimetry, making it rhenium-188 an ideal theranostic agent in clinical nuclear medicine. Rhenium-188 is readily available from a 188W/188Re generator, which enables the use of non-carrier added (nca) rhenium- 188 in hospitals and remote locations. In light of the recent shortage of 188W/188Re generators on the market, we undertook efforts to prepare our own generator to provide a constant rhenium-188 supply for our research into 188Re-based radiopharmaceuticals. Here we present the in-house development of the 188W/188Re generator and the first applications of this rhenium-188 in the development of novel 188Re-chelators.
|Name||Nuclear Medicine and Biology|
|Conference||2022 - TERACHEM|
|Period||2022-09-14 → 2022-09-17|